Jame Abraham: we need to have a better understanding of HER-2 ultra-low and how to define it
Jame Abraham shared on X:
“New approval for TDXd for metastatic breast cancer with HER – 2 low and ultra-low ( HER -2 IHC 2+ ) FISH -) IHC 1+, HER -2 – >0, <1 +-.
We need to have a better understanding of HER -2 ultra-low and how to define it!”
Read further.
Source: Jame Abraham/X
Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.
Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023